1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Analyzing the Global Diabetes Market 2016

Analyzing the Global Diabetes Market 2016

  • September 2016
  • -
  • Aruvian's R'search
  • -
  • 195 pages

Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. Oral anti-diabetics were the leading category of drugs in 2014 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin products increased significantly as well.

Anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years. The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.

Top players in the global diabetes market are Novo Nordisk, Eli Lilly, Merck & Co., amongst others. Significant R&D has been observed in the pre-insulin market leading to the development of several novel and safer therapies. The comparative performance of these therapies, such as the DPP-IV inhibitors and GLP-1 analogs is expected to shape the diabetes market landscape in the long term.

Aruvian Research analyzes the Global Diabetes Market in its research offering Analyzing the Global Diabetes Market. The report is a comprehensive analysis of the global diabetes industry.

The report begins with an introduction to diabetes. We analyze the basics of diabetes such as the different types of diabetes including Type 1 diabetes, Type 2 diabetes, gestational diabetes, and others. Complications with diabetes, how the disease is diagnosed, how the extent of diabetes is estimated, diabetes pathophysiology, and the treatment for diabetes are analyzed in this section. We also look at diabetes epidemiology.

Moving to the next section, we analyze the global diabetes market through a market overview and an analysis of the market by diabetes drug classes. We take the drug classes to be insulin, insulin secretagogues, insulin sensitizers, and incretin mimetics. We also analyze the industry through industry segmentation and an analysis of the leading industry products such as Lantus, Actos, Januvia, Novorapid, and others. We look at the sales figures of the leading 20 products in the industry.

An analysis of the global diabetes industry is not complete without an analysis of the market for insulin. We analyze the market for insulin through an industry overview, and an analysis of the market for human insulin. Within the market for human insulin we analyze the following market segments: fast-acting human insulin analogs, intermediate-acting human insulin analogs, long-acting human insulin analogs, and intermediate and fast-acting human insulin analogs.

With the rapid advances in technology, it is no wonder that there are now many novel emerging drug classes available for the treatment of diabetes. Some of these novel emerging drug classes for diabetes treatment are analyzed in our report. We analyze alpha-glucosidase inhibitors such as Basen, biguanides such as glucophages, DPP-IV inhibitors such as Januvia, glitazones such as Actos, GLP-1 agonists such as Victoza and Byetta, sulfonylureas such as Amaryl, amongst others.

Moving on, we carry out an analysis of some of the key molecules used in the treatment of diabetes today. Some of the molecules analyzed include Degludec, Victoza, Syncria, amongst others.

An analysis of the diabetes market in India and China, two of the countries with the largest prevalence of diabetes, is also included, along with a look at industry research and development.

Competition in the industry is analyzed in the report, following which we move on to the analysis of the major players in the global diabetes industry. Players in the industry are analyzed through a corporate profile, an analysis of their major business segments, their major products and services offered, a financial analysis, and an analysis of their presence in the diabetes market. We also look at their diabetes R&D pipeline, along with the company strategy for future growth in the diabetes industry. A SWOT analysis of the players completes the analysis of the major industry contributors.

Future perspective of the global diabetes market completes this in-depth profile of the global diabetes market from Aruvian Research.

Table Of Contents

Analyzing the Global Diabetes Market 2016
A. Executive Summary

B. Introduction to Diabetes
B.1 What is Diabetes?
B.2 Type 1 Diabetes
B.3 Type 2 Diabetes
B.4 Gestational Diabetes
B.5 Other Types of Diabetes (Pre-diabetes)
B.6 Complications with Diabetes
B.7 Diagnosing Diabetes
B.8 Estimating the Extent of Diabetes
B.9 Diabetes Pathophysiology
B.10 Treatment for Diabetes
B.11 Diabetes Epidemiology

C. Global Diabetes Market
C.1 Market Overview
C.2 Market Analysis by Diabetes Drug Classes
C.2.1 Insulin
C.2.2 Insulin Secretagogues
C.2.3 Insulin Sensitizers
C.2.4 Incretin Mimetics
C.3 Industry Segmentation
C.4 Leading Industry Products

D. Market for Insulin
D.1 Market Overview
D.2 Market for Human Insulin
D.2.1 Market for Fast-acting Human Insulin Analogs
D.2.2 Market for Intermediate-acting Human Insulin Analogs
D.2.3 Market for Long-acting Human Insulin Analogs
D.2.4 Market for Intermediate and Fast-acting Human Insulin Analogs

E. Analysis of Novel Emerging Drug Classes for Diabetes Treatment
E.1 Alpha-glucosidase Inhibitors
E.1.1 Product Analysis: Basen
E.2 Biguanides
E.2.1 Product Analysis: Glucophage
E.3 DPP-IV Inhibitors
E.3.1 Product Analysis: Januvia
E.4 Glitazones
E.4.1 Product Analysis: Actos
E.4.2 Product Analysis: Avandia
E.5 GLP-1 Agonists
E.5.1 Product Analysis: Victoza
E.5.2 Product Analysis: Byetta
E.6 Sulfonylureas
E.6.1 Product Analysis: Amaryl
E.7 DPP-IV versus GLP-1

F. Analysis of Key Molecules
F.1 Bydureon
F.2 Dapagliflozin
F.3 Degludec
F.4 Glucokinase Activators
F.5 Lixisenatide
F.6 Syncria
F.7 Tradjenta
F.8 Victoza

G. Industry Research and Development
G.1 Research on Insulin Therapy Areas
G.2 Clinical Evidence on the Role of Certain Elements in the Body
G.3 Addressing Cardiovascular Risk Factors in Diabetes Treatment
G.4 US FDA Cardiovascular Risk Evaluation Guidelines

H. Diabetes Market in India
H.1 Market Overview
H.2 Challenges Facing the Industry

I. Diabetes Market in China
I.1 Market Overview
I.2 Challenges Facing the Industry

J. Competition in the Industry

K. Leading Industry Contributors
K.1 Eli Lilly and Co.
K.1.1 Corporate Profile
K.1.2 Business Segment Analysis
K.1.3 Major Products and Services
K.1.4 Financial Analysis
K.1.5 Presence in the Diabetes Market
K.1.6 Diabetes RandD Pipeline
K.1.7 Company Strategy in the Global Diabetes Market
K.1.8 SWOT Analysis
K.2 Merck and Co.
K.2.1 Corporate Profile
K.2.2 Business Segment Analysis
K.2.3 Major Products and Services
K.2.4 Financial Analysis
K.2.5 Presence in the Diabetes Market
K.2.6 Diabetes RandD Pipeline
K.2.7 Company Strategy in the Global Diabetes Market
K.2.8 SWOT Analysis
K.3 Novo Nordisk
K.3.1 Corporate Profile
K.3.2 Business Segment Analysis
K.3.3 Major Products and Services
K.3.4 Financial Analysis
K.3.5 Presence in the Diabetes Market
K.3.6 Diabetes RandD Pipeline
K.3.7 Company Strategy in the Global Diabetes Market
K.3.8 SWOT Analysis
K.4 Sanofi SA
K.4.1 Corporate Profile
K.4.2 Business Segment Analysis
K.4.3 Major Products and Services
K.4.4 Financial Analysis
K.4.5 Presence in the Diabetes Market
K.4.6 Diabetes RandD Pipeline
K.4.7 Company Strategy in the Global Diabetes Market
K.4.8 SWOT Analysis
K.5 Takeda Pharmaceutical Company
K.5.1 Corporate Profile
K.5.2 Business Segment Analysis
K.5.3 Major Products and Services
K.5.4 Financial Analysis
K.5.5 Presence in the Diabetes Market
K.5.6 Diabetes RandD Pipeline
K.5.7 Company Strategy in the Global Diabetes Market
K.5.8 SWOT Analysis

L. Global Diabetes Market: Future Perspective
L.1 Forecast for Top Anti-diabetic Products
L.2 Forecast for Top Anti-diabetic Molecules

M. Glossary of Terms

List of Figures

Figure 1: Production of Insulin
Figure 2: Algorithm for Treatment of Diabetes
Figure 3: Market Share of Diabetes by Country (%), 2014
Figure 4: Various Diabetes Drug Classes and their Market Position in 2014
Figure 5: How GLP-1 Agonists Work
Figure 6: How Degludec Works
Figure 7: Overview of Degludec
Figure 8: Mechanism of Glucose Phosphorylation
Figure 9: How GK Activators in Type 2 Diabetes Work
Figure 10: Unmet Needs in Diabetes Treatment
Figure 11: Prevalence of Diabetes in India in 2014
Figure 12: Diabetes Products of Eli Lilly by Drug Class in 2014
Figure 13: Diabetes Products of Novo Nordisk by Drug Class in 2014
Figure 14: Diabetes Products of Sanofi SA by Drug Class in 2014
Figure 15: Diabetes Products of Takeda Pharmaceutical by Drug Class in 2014

List of Tables

Table 1: Prevalence of Diabetes by Region (2014-2030)
Table 2: Diabetes Prevalence in Leading 20 Countries, 2014 and 2030
Table 3: Sales of Anti-diabetic Drugs by Class (USD Million), 2014
Table 4: Diabetes Market Segmentation by Drug Class (USD Million) 2014-2020
Table 5: Leading 10 Diabetes Products (Sales and Market Share) (USD Million) 2014
Table 6: More Leading Diabetes Products (Sales and Market Share) (USD Million), 2014
Table 7: Different Types of Insulin Available and their Characteristics
Table 8: Sales of Human Insulin by Segments (USD Million), 2014
Table 9: Market Leaders in Fast-Acting Insulin Class (Sales and Leading Brands) (USD Million), 2014
Table 10: Characteristics of Humalog by Eli Lilly
Table 11: Characteristics of NovoRapid by Novo Nordisk
Table 12: Table 9: Market Leaders in Intermediate-Acting Insulin Class (Sales and Leading Brands) (USD Million), 2014
Table 13: Market Leaders in Long-Acting Insulin Class (Sales and Leading Brands) (USD Million), 2014
Table 14: Characteristics of Lantus by Sanofi
Table 15: Market Leaders in Intermediate and Fast-Acting Insulin Class (Sales and Leading Brands) (USD Million), 2014
Table 16: Characteristics of NovoMix by Novo Nordisk
Table 17: Major Products and their Sales in the Alpha Glucosidase Inhibitors Drug Class (USD Million) in 2014
Table 18: Major Products and their Sales in the Biguanides Drug Class (USD Million) in 2014
Table 19: Major Products and their Sales in the DPP-IV Drug Class (USD Million) in 2014
Table 20: Factors Impacting the Market for Januvia
Table 21: Major Products and their Sales in the Glitazone Drug Class (USD Million) in 2014
Table 22: Major Products and their Sales in the GLP-1 Analogue Drug Class (USD Million) in 2014
Table 23: Major Products and their Sales in the Sulfonylureas Drug Class (USD Million) in 2014
Table 24: Comparison of GLP-1 Agonists and DPP-IV Inhibitors
Table 25: Phase III Clinical Trials Results of Dapagliflozin
Table 26: Sales of Market Leaders in 2014
Table 27: Anti-diabetic Products of Eli Lilly in 2014 (Sales and Market Share)
Table 28: Anti-diabetic Products of Merck and Co. in 2014 (Sales and Market Share)
Table 29: Diabetes RandD Pipeline of Merck and Co.
Table 30: Anti-diabetic Products of Novo Nordisk in 2014 (Sales and Market Share)
Table 31: Diabetes RandD Pipeline of Novo Nordisk
Table 32: Anti-diabetic Products of Sanofi SA in 2014 (Sales and Market Share)
Table 33: Diabetes RandD Pipeline of Sanofi SA
Table 34: Anti-diabetic Products of Takeda Pharmaceutical in 2014 (Sales and Market Share)
Table 35: Diabetes RandD Pipeline of Takeda Pharmaceutical
Table 36: Leading Anti-Diabetic Products Sales Forecast (USD Million) (2014-2020)
Table 37: Leading Anti-Diabetic Molecules Sales Forecast (USD Million) (2014-2020)

Companies Mentioned
Takeda Pharmaceutical Company
Sanofi SA
Novo Nordisk
Merck and Co.
Eli Lilly and Co.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

  • $ 4995
  • Industry report
  • August 2016
  • by GBI Research

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment Summary Diabetes is a chronic metabolic disease ...

Global Needle Free Diabetes Management Market Analysis & Trends – Device Type (Artificial Pancreas Devices & Systems, Diagnostic Devices, Treatment Devices), Management Type - Forecast to 2025

Global Needle Free Diabetes Management Market Analysis & Trends – Device Type (Artificial Pancreas Devices & Systems, Diagnostic Devices, Treatment Devices), Management Type - Forecast to 2025

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Needle Free Diabetes Management Market is poised to grow at a CAGR of around 17.6% over the next decade to reach approximately $16.2 billion by 2025. Some of the prominent trends that the market ...

Global Diabetes Management Market Report 2016

Global Diabetes Management Market Report 2016

  • $ 2850
  • Industry report
  • August 2016
  • by 9Dimen Research

2016 Global Diabetes Management Report is a professional and in-depth research report on the world's major regional market conditions of the Diabetes Management industry, focusing on the main regions (North ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.